X

Trial Profile

A phase 1 trial of UDP-003 for the treatment of atherosclerosis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UDP-003 (Primary)
Indications Atherosclerosis
Focus Adverse reactions; First in man
Sponsors Cyclarity Therapeutics

Most Recent Events

07 Jan 2025 According to a Cyclarity Therapeutics media release, the company has received approval for the first in human trial. The trial will be conducted at CMAX, Australia in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients with Acute Coronary Syndrome (ACS).
28 Sep 2021 New trial record
23 Sep 2021 According to an underdog pharmaceuticals, the company expect to begin clinical trials in 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com